One of Israel’s NASDAQ listed bio-techs BiolineRX Ltd. reported positive results for its Phase Ia clinical trial of its drug, BL-1021, for the treatment of chronic neuropathic pain due to damaged nerves. It is associated with conditions including shingles, diabetes and cancer, affecting 1-3% of the world’s population.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000703939&fid=1725